|
週次 |
日期 |
單元主題 |
|
第1週 |
2/17 |
GPCR-based (or GPCR-targeted) drug discovery (including antibodies, biased ligands, allosteric modulators, etc.) |
|
第2週 |
2/24 |
the mitochondrion as a toxicological and pharmacological target |
|
第3週 |
3/03 |
antibodies (or more) against membrane proteins (這是GPCR-based drug discovery的延伸) |
|
第4週 |
3/10 |
new target(s) for drug discovery: antibacterials, neurodegenerative disease, etc. |
|
第5週 |
3/17 |
kinase inhibitor (討論的主題不侷限於cancer, 也許可以是inflammation, autoimmunity...) |
|
第6週 |
3/24 |
drugging the epigenome (including the writer, eraser, and reader proteins of histone) |
|
第7週 |
3/31 |
cardio-metabolic drug targets (Cardiovascular disease, diabetes, obesity and dyslipidemia, though traditionally treated as separate entities, are often conditions that appear together in individuals because of defects in underlying metabolic processes.) |
|
第8週 |
4/07 |
nuclear (hormone) receptors |
|
第9週 |
4/14 |
期中考週 |
|
第10週 |
4/21 |
new target(s) for drug discovery: antibacterials, neurodegenerative disease, etc. |
|
第11週 |
4/28 |
nuclear (hormone) receptors |
|
第12週 |
5/05 |
antibodies (or more) against membrane proteins (這是GPCR-based drug discovery的延伸) |
|
第13週 |
5/12 |
cardio-metabolic drug targets (Cardiovascular disease, diabetes, obesity and dyslipidemia, though traditionally treated as separate entities, are often conditions that appear together in individuals because of defects in underlying metabolic processes.) |
|
第14週 |
5/19 |
the mitochondrion as a toxicological and pharmacological target |
|
第15週 |
5/26 |
drugging the epigenome (including the writer, eraser, and reader proteins of histone) |
|
第16週 |
6/02 |
端午節，停課一次 |
|
第17週 |
6/09 |
kinase inhibitor (討論的主題不侷限於cancer, 也許可以是inflammation, autoimmunity...)/GPCR-based (or GPCR-targeted) drug discovery (including antibodies, biased ligands, allosteric modulators, etc.) |